Safety of 8-aminoquinolines given to people with G6PD deficiency: protocol for systematic review of prospective studies. Issue 5 (14th May 2014)

• Record Type: Journal Article
• Authors: Uthman, Olalekan A; Saunders, Rachel; Sinclair, David; Graves, Patricia; Gelband, Hellen; Clarke, Aileen; Garner, Paul
• Is Part Of: BMJ open. Volume 4:Issue 5(2014)
• Publication Date: 2014-05-14
• Subjects: Preventive Medicine -- Public Health -- Infectious Diseases; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2013-004664
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Introduction: A single dose or short course of primaquine given to people infected with malaria may reduce transmission of Plasmodium falciparum through its effects on gametocytes. Primaquine is also known to cause haemolysis in people with variants of glucose-6-phosphate dehydrogenase (G6PD) deficiency. The objective of this systematic review was to assess the risk of adverse effects in people with G6PD deficiency given primaquine or other 8-aminoquinoline (8AQ) as a single dose or short course (less than 7 days). Methods and analysis: We will search the following databases: Cochrane Infectious Diseases Group Specialized Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and LILACS. Prospective cohort studies, randomised and quasi-randomised trials that evaluated 8AQs for whatever reason in adults or children with a known G6PD deficiency will be included. Two authors will independently assess each study for eligibility, risk of bias and extract data. Ethics and dissemination: This systematic review will be published in a peer-reviewed journal. Brief reports of the review findings will be disseminated directly to the appropriate audiences and the WHO Technical Expert Group in Malaria Chemotherapy. As no primary data collection will be undertaken, no additional formal ethical assessment and informed consent are required. Protocol registration in PROSPERO: The protocol is registered with PROSPERO, registration number CRD42013006518.